China's NMPA Accepts Junshi Biosciences' NDAs for Toripalimab Subcutaneous Injection

Shanghai Junshi Biosciences announced that China's National Medical Products Administration (NMPA) has accepted its New Drug Applications (NDAs) for a subcutaneous formulation of toripalimab. The applications cover 12 different tumor indications, marking a significant milestone in the company's oncology pipeline development. Notably, JS001sc is the first domestic anti-PD-1 monoclonal antibody in a subcutaneous formulation to reach the marketing application stage in China. This regulatory acceptance is a critical step toward commercializing a more convenient delivery method compared to traditional intravenous options. Junshi Biosciences, listed on both the Hong Kong and Shanghai stock exchanges, expects this formulation to provide a competitive edge in the PD-1 market. The move highlights the company's ongoing commitment to innovation within the rapidly evolving Chinese pharmaceutical sector.

Sources:globenewswire.combiopharmaboardroom.comaktiencheck.detipranks.com